Author(s): Paul Richardson, Albert Oriol Rocafiguera, Meral Beksac, et al. Abstract: S847 Session topic: 14. Myeloma and other monoclonal gammopathies – Clinical Background Despite recent therapeutic advances, multiple myeloma (MM) remains an incurable plasma cell malignancy. Pomalidomide (POM) is a standard-of-care treatment in relapsed or refractory MM (RRMM) and has demonstrated synergistic...
Pro zobrazení tohoto obsahu je třeba být přihlášen.